Abstract
Amyloid-beta (Aβ) immunotherapy has received considerable attention as a promising approach for reducing the level of Aβ in the CNS of Alzheimers disease patients. However, the first Phase II clinical trial, for the immune therapy AN1792, was halted when a subset of those immunized with Aβ42 developed adverse events in the central nervous system. In addition, data from the trial indicated that there was a low percentage of responders and generally low to moderate titers in the patients that received the vaccine. Generated antibodies reduced β-amyloid deposits in the parenchyma of patients brains, but no reduction in soluble Aβ or significant improvements in cognitive function of patients were observed. These data and data from pre-clinical studies suggest that reduction in the most toxic oligomeric forms of Aβ is important for prevention or slowing down of the progression of cognitive decline, and that vaccination should be started prior to irreversible accumulation of the oligomeric Aβ, at the early stages of AD. Protective immunotherapy requires a development of safe and effective strategy for Aβ immunotherapy. In this review, the rationale for developing epitope vaccines for the treatment of AD will be discussed. We believe that an epitope vaccine will induce an adequate anti-Aβ antibody response in the absence of potentially adverse self T cell-mediated events, making it possible to start immunization at the early stages of AD.
Keywords: Alzheimer's Disease, peptide vaccine, DNA vaccine, epitope vaccine, immunotherapy
CNS & Neurological Disorders - Drug Targets
Title: Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy
Volume: 8 Issue: 2
Author(s): Anahit Ghochikyan
Affiliation:
Keywords: Alzheimer's Disease, peptide vaccine, DNA vaccine, epitope vaccine, immunotherapy
Abstract: Amyloid-beta (Aβ) immunotherapy has received considerable attention as a promising approach for reducing the level of Aβ in the CNS of Alzheimers disease patients. However, the first Phase II clinical trial, for the immune therapy AN1792, was halted when a subset of those immunized with Aβ42 developed adverse events in the central nervous system. In addition, data from the trial indicated that there was a low percentage of responders and generally low to moderate titers in the patients that received the vaccine. Generated antibodies reduced β-amyloid deposits in the parenchyma of patients brains, but no reduction in soluble Aβ or significant improvements in cognitive function of patients were observed. These data and data from pre-clinical studies suggest that reduction in the most toxic oligomeric forms of Aβ is important for prevention or slowing down of the progression of cognitive decline, and that vaccination should be started prior to irreversible accumulation of the oligomeric Aβ, at the early stages of AD. Protective immunotherapy requires a development of safe and effective strategy for Aβ immunotherapy. In this review, the rationale for developing epitope vaccines for the treatment of AD will be discussed. We believe that an epitope vaccine will induce an adequate anti-Aβ antibody response in the absence of potentially adverse self T cell-mediated events, making it possible to start immunization at the early stages of AD.
Export Options
About this article
Cite this article as:
Ghochikyan Anahit, Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy, CNS & Neurological Disorders - Drug Targets 2009; 8 (2) . https://dx.doi.org/10.2174/187152709787847298
DOI https://dx.doi.org/10.2174/187152709787847298 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Role of Platelets in Angiogenesis in Health and Disease
Current Angiogenesis (Discontinued) Antibody-Mediated Endothelial Cell Damage Via Nitric Oxide
Current Pharmaceutical Design The Role of Melanin to Dissociate Oxygen from Water to Treat Retinopathy of Prematurity
Central Nervous System Agents in Medicinal Chemistry The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer
Current Gene Therapy Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry The Treatment of Autoimmune Hepatitis
Current Clinical Pharmacology Activation of the Liver X Receptor Inhibits Th17 and Th1 Responses in Behcet`s Disease and Vogt-Koyanagi-Harada Disease
Current Molecular Medicine Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews Excess Exposure to Insulin Is the Primary Cause of Insulin Resistance and its Associated Atherosclerosis
Current Molecular Pharmacology Editorial: MRI of the Small Bowel
Current Medical Imaging Interventional Radiology in Paediatrics
Current Pediatric Reviews Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Vincristine-Induced Seizure Potentiated by Itraconazole Following RCHOP Chemotherapy for Diffuse Large B-Cell Lymphoma
Current Drug Safety Endothelial Dysfunction in Cardiac Allograft Vasculopathy: Potential Pharmacological Interventions
Current Vascular Pharmacology Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery